Research programme: protease activated cancer therapy - Dendreon

Drug Profile

Research programme: protease activated cancer therapy - Dendreon

Alternative Names: CVS 10290; PACT; Research programme: protease activated cancer therapy - Corvas

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class
  • Mechanism of Action Protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
  • 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC
  • 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top